Post-marketing studies of ED therapies under review

AUA guideline warns of conflicts of interest influencing PDE-5 comparison trials

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria